822 A1A North
Ponte Vedra, FL 32082
904 300 0701
Full-time employees: 3
|Mr. Quang X. Pham||Chairman & CEO||822.17k||N/A||1965|
|Mr. Matthew K. Szot CPA, CPA||Co-Founder & CFO||359.61k||N/A||1974|
|Dr. Douglas W. Losordo FACC, FAHA, M.D.||Chief Medical Officer||23.36k||N/A||1958|
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Cadrenal Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.